2024-2032 年按药物类别、配销通路和地区分類的 HIV 药物市场报告

IMARC Group年全球爱滋病药物市场规模达317亿美元。由于人们的认识和预防工作不断增强，爱滋病毒/爱滋病在全球范围内的流行率不断上升，以及专注于更有效和更容易获得的抗逆转录病毒疗法的各种研究和开发计划正在进行，推动了该市场的稳定成长。

HIV药物市场分析：

市场成长与规模：近年来，全球爱滋病毒药物市场稳定成长。由于爱滋病毒/爱滋病盛行率的增加和治疗方案的扩大，预计这一数字将继续增长。

技术进步：技术进步导致了更有效和更耐受的抗逆转录病毒药物的开发。改进的药物传递机制（例如长效注射剂）提高了治疗顺从性。此外，远距医疗和行动健康应用程式正在增强患者管​​理和监控。

产业应用：爱滋病毒药物市场为全球爱滋病毒/爱滋病患者提供服务。它也可用于预防性治疗，包括针对高风险族群的暴露前预防 (PrEP)。此外，该行业与政府、非政府组织和医疗保健提供者合作，以确保获得药物和护理。

地理趋势：撒哈拉以南非洲和亚洲部分地区等高流行地区推动了庞大的需求。由于可以获得先进的治疗方法，北美和欧洲也拥有庞大的市场。此外，拉丁美洲和亚太地区的新兴市场也在成长。

竞争格局：市场的特点是竞争激烈，主要参与者专注于创新、併购（M&A）以及扩大全球足迹。这些策略旨在增强产品组合、满足特定产业需求并应对不断发展的市场挑战。

挑战与机会：挑战包括需要持续治疗、抗药性以及某些药物的高成本。机会在于开发更实惠、更容易获得的药物、扩大预防工作以及研究潜在的治疗方法。

未来展望：爱滋病毒药物市场的未来充满希望，正在进行的研究旨在功能性治癒和长效治疗。增加获得药物和预防方法的机会仍然是全球卫生的优先事项。此外，在技术进步和扩大治疗计划的推动下，市场预计将继续增长。

HIV药物市场趋势：

爱滋病毒/爱滋病的盛行率不断上升

全球爱滋病毒/爱滋病流行仍然是一个重要的公共卫生议题，截至 2021 年，全球约有 3,800 万名爱滋病毒感染者。随着新病例不断出现，特别是在预防措施有限的地区，对有效治疗方案的需求日益增加。爱滋病毒的高传播率，特别是在撒哈拉以南非洲以及亚洲和东欧的某些地区，需要持续和增加抗逆转录病毒治疗（ART）的可用性，而这仍然是爱滋病毒治疗的基石。

治疗方法的进步

近年来，爱滋病毒治疗方案取得了重大进展，促进了爱滋病毒药物市场的成长。结合多种抗逆转录病毒药物的高效抗逆转录病毒疗法（HAART）的发展彻底改变了爱滋病毒治疗。这些进步不仅提高了爱滋病毒药物的有效性，也减少了副作用，从而提高了患者的依从性和治疗效果。整合酶抑制剂等新药物类别的引入和长效注射剂的开发进一步扩大了治疗选择，满足不同患者的需求和偏好。

提高患者的意识

提高意识和诊断率对于推动爱滋病毒药物市场至关重要。公共卫生运动和教育措施提高了人们对爱滋病毒/爱滋病的了解，减少了耻辱并鼓励更多的人接受检测。早期和改进的诊断技术也有助于提高爱滋病毒检出率，从而增加寻求治疗的人数。诊断率的上升，加上不断努力改善爱滋病毒检测，特别是在流行率高的地区，继续推动对有效爱滋病毒药物的需求。

联合疗法日益受到关注

联合疗法已成为爱滋病毒治疗的标准，涉及使用多种抗逆转录病毒药物来增强疗效并防止抗药性。固定剂量组合 (FDC) 的开发和批准简化了治疗方案，提高了依从性和患者治疗效果。製药公司越来越注重开发这些联合疗法，与单一疗法相比，联合疗法具有多种优势，包括减少药物负担和提高患者依从性。医疗保健提供者和患者对联合疗法的日益偏好是推动爱滋病毒药物市场的关键因素。

目录

第一章：前言

第 2 章：范围与方法

• 研究目的
• 利害关係人
• 资料来源
  • 主要资源
  • 二手资料
• 市场预测
  • 自下而上的方法
  • 自上而下的方法
• 预测方法

第 3 章：执行摘要

第 4 章：简介

• 概述
• 主要行业趋势

第 5 章：全球 HIV 药物市场

• 市场概况
• 市场业绩
• COVID-19 的影响
• 价格分析
• 市场区隔：依药品类别
• 市场区隔：按配销通路
• 市场区隔：按地区
• 市场预测
• SWOT分析
  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁
• 价值链分析
  • 概述
  • 研究与开发
  • 原物料采购
  • 製造业
  • 行销
  • 分配
  • 最终用途
• 波特五力分析
  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 6 章：市场区隔：依药物类别

• 核苷逆转录酶抑制剂
  • 市场走向
  • 市场预测
• 多类别组合产品
  • 市场走向
  • 市场预测
• 蛋白酶抑制剂
  • 市场走向
  • 市场预测
• HIV 整合酶链转移抑制剂
  • 市场走向
  • 市场预测
• 非核苷逆转录酶抑制剂
  • 市场走向
  • 市场预测
• 进入抑制剂 - CCR5 共受体拮抗剂
  • 市场走向
  • 市场预测
• 融合抑制剂及其他
  • 市场走向
  • 市场预测

第 7 章：市场区隔：按配销通路

• 医院药房
  • 市场走向
  • 市场预测
• 零售药局
  • 市场走向
  • 市场预测
• 网路药局
  • 市场走向
  • 市场预测
• 其他的
  • 市场走向
  • 市场预测

第 8 章：市场区隔：按地区

• 北美洲
  • 市场走向
  • 市场预测
• 欧洲
  • 市场走向
  • 市场预测
• 亚太地区
  • 市场走向
  • 市场预测
• 中东和非洲
  • 市场走向
  • 市场预测
• 拉丁美洲
  • 市场走向
  • 市场预测

第 9 章：HIV 药物生产流程

• 产品概述
• 原料要求
• 製造流程
• 关键成功因素与风险因素

第 10 章：竞争格局

• 市场结构
• 市场区隔：按关键参与者
• 关键参与者简介
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • ViiV Healthcare
  • AbbVie
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Cipla Limited
  • Daiichi Sankyo
  • Emcure
  • Hetero Drugs
  • Mylan

The global HIV drugs market size reached US$ 31.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 43.9 Billion by 2032, exhibiting a growth rate (CAGR) of 3.6% during 2024-2032. The market is experiencing steady growth driven by the increasing awareness and prevention efforts, the growing prevalence of HIV/AIDS across the globe, and ongoing various research and development initiatives focused on more effective and accessible antiretroviral therapies.

HIV Drugs Market Analysis:

Market Growth and Size: The global HIV drugs market has witnessed steady growth in recent years. It is expected to continue growing due to the increasing prevalence of HIV/AIDS and the expansion of treatment programs.

Technological Advancements: Technological advancements have led to the development of more potent and tolerable antiretroviral drugs. Improved drug delivery mechanisms, such as long-acting injectables, have increased treatment adherence. Besides, telemedicine and mobile health apps are enhancing patient management and monitoring.

Industry Applications: The HIV drugs market serves patients living with HIV/AIDS worldwide. It also has applications in preventive treatments, including pre-exposure prophylaxis (PrEP) for high-risk populations. Moreover, the industry collaborates with governments, NGOs, and healthcare providers to ensure access to medications and care.

Geographical Trends: High prevalence regions like sub-Saharan Africa and parts of Asia drive significant demand. North America and Europe also have substantial markets due to access to advanced treatments. Besides, emerging markets in Latin America and Asia-Pacific are witnessing growth.

Competitive Landscape: The market is characterized by intense competition with key players focusing on innovation, mergers and acquisitions (M&A), and expanding their global footprint. These strategies aim to enhance product portfolios, meet specific industry needs, and address the challenges of an evolving market.

Challenges and Opportunities: Challenges include the need for continuous treatment, drug resistance, and the high cost of some medications. Opportunities lie in developing more affordable and accessible drugs, expanding prevention efforts, and research into potential cures.

Future Outlook: The future of the HIV drugs market holds promise, with ongoing research aiming for a functional cure and long-acting therapies. Increased access to medications and prevention methods remains a global health priority. Moreover, market growth is expected to continue, driven by technological advancements and expanded treatment programs.

HIV Drugs Market Trends:

The growing prevalence of HIV/AIDS

The global HIV/AIDS epidemic remains a critical public health issue, with approximately 38 million people living with HIV worldwide as of 2021. This increased prevalence directly drives the demand for HIV drugs. As new cases continue to emerge, especially in regions with limited access to preventive measures, the need for effective treatment options intensifies. The high transmission rate of HIV, particularly in sub-Saharan Africa and certain parts of Asia and Eastern Europe, necessitates sustained and increased availability of antiretroviral therapy (ART), which remains the cornerstone of HIV treatment.

Advancements in treatments

Recent years have witnessed significant advancements in HIV treatment regimens, contributing to the growth of the HIV drugs market. The development of highly active antiretroviral therapy (HAART), which combines multiple antiretroviral drugs, has revolutionized HIV treatment. These advancements have not only improved the effectiveness of HIV drugs but also reduced side effects, leading to better patient adherence and outcomes. The introduction of newer drug classes like integrase inhibitors and the development of long-acting injectables have further expanded treatment options, catering to diverse patient needs and preferences.

Increasing awareness among patients

Enhanced awareness and diagnostic rates are pivotal in driving the market for HIV drugs. Public health campaigns and educational initiatives have increased the understanding of HIV/AIDS, reducing stigma and encouraging more people to get tested. Early and improved diagnostic techniques have also contributed to higher detection rates of HIV, subsequently increasing the number of individuals seeking treatment. This rise in diagnosis, coupled with ongoing efforts to improve HIV testing, particularly in regions with high prevalence rates, continues to fuel the demand for effective HIV medications.

Rising focus on combination therapies

Combination therapies have become a standard in HIV treatment, involving the use of multiple antiretroviral drugs to enhance efficacy and prevent drug resistance. The development and approval of fixed-dose combinations (FDCs) have simplified treatment regimens, improving adherence and patient outcomes. Pharmaceutical companies are increasingly focusing on developing these combination therapies, which offer several advantages over monotherapy, including reduced pill burden and improved patient compliance. The growing preference for combination therapies among healthcare providers and patients is a key factor driving the market for HIV drugs.

HIV Drugs Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2024-2032. Our report has categorized the market based on drug class and distribution channel.

Breakup by Drug Class:

Nucleoside Reverse Transcriptase Inhibitors

Multi-Class Combination Products

Protease Inhibitors

HIV Integrase Strand Transfer Inhibitors

Non-Nucleoside Reverse Transcriptase Inhibitors

Entry Inhibitors - CCR5 Co-Receptor Antagonist

Fusion Inhibitors and Others

Nucleoside reverse transcriptase inhibitors accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the drug class. This includes nucleoside reverse transcriptase inhibitors, multi-class combination products, protease inhibitors, HIV integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, entry inhibitors - CCR5 co-receptor antagonist, fusion inhibitors and others. According to the report, nucleoside reverse transcriptase inhibitors represented the largest segment.

NRTIs, also known as nucleoside analogs, are a crucial class of HIV drugs. They inhibit the action of reverse transcriptase, an enzyme the virus uses to replicate its genetic material. NRTIs are often included as a backbone in HIV treatment regimens due to their effectiveness and safety. They are widely used as a first-line therapy, either alone or in combination with other drug classes, making them the largest segment in the HIV drugs market.

Multi-class combination products refer to antiretroviral therapies that combine drugs from different classes. These combinations are designed to target HIV from multiple angles, reducing the risk of resistance development and increasing treatment efficacy. They offer convenience by simplifying the regimen for patients and are often prescribed when NRTIs alone are insufficient.

Protease inhibitors (PIs) interfere with the protease enzyme, necessary for HIV maturation and replication. PIs are a vital part of combination therapies and have been instrumental in reducing HIV-related deaths. They are used in conjunction with other drug classes to suppress viral replication effectively.

Integrase strand transfer inhibitors (INSTIs) block the integration of viral genetic material into the host cell's DNA, preventing viral replication. INSTIs have gained prominence due to their potent antiviral activity and favorable side-effect profiles. They are commonly used in first-line regimens and in treatment-experienced patients.

NNRTIs are another class of HIV drugs that target reverse transcriptase but do so differently from NRTIs. They bind to the enzyme and inhibit its activity. NNRTIs are often part of combination therapies and are especially useful in cases where resistance to other drug classes has developed.

CCR5 co-receptor antagonists block the CCR5 receptor on the surface of immune cells, preventing HIV from entering and infecting these cells. They are typically used in patients who are CCR5-tropic, meaning their virus uses the CCR5 co-receptor for entry.

Fusion inhibitors work by preventing the virus from fusing with the host cell membrane, thus inhibiting viral entry. This class of drugs is less commonly used than others due to their complex administration (usually by injection).

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Others

Hospital pharmacies holds the largest share in the industry

A detailed breakup and analysis of the market based on the distribution channel have also been provided in the report. This includes hospital pharmacies, retail pharmacies, online pharmacies and others. According to the report, hospital pharmacies accounted for the largest market share.

Hospital pharmacies constitute the largest segment in the HIV drugs market, primarily due to their role as essential providers of antiretroviral therapies to inpatients and outpatients living with HIV/AIDS. These pharmacies operate within healthcare institutions, including public and private hospitals, clinics, and specialty HIV treatment centers. They offer a wide range of HIV medications, ensuring access to the latest antiretroviral therapies for patients. Hospital pharmacies play a crucial role in medication management, counseling, and monitoring, contributing significantly to patient adherence and treatment outcomes. With a direct link to healthcare providers, hospital pharmacies are pivotal in the comprehensive care and management of HIV/AIDS patients.

Retail pharmacies, including independent drugstores and chain pharmacies, form another vital segment in the HIV drugs market. They serve as accessible points of care for individuals seeking prescription medications, including antiretroviral drugs. Retail pharmacies provide convenience and privacy for patients picking up their HIV medications. They play a critical role in supporting medication adherence through counseling and refill reminders. The retail segment is especially important for patients in urban and suburban areas who may not access hospital-based care regularly.

Online pharmacies have gained prominence as a convenient and discrete source of HIV medications. This segment caters to individuals who prefer the convenience of ordering their antiretroviral drugs online and having them delivered to their doorstep. Online pharmacies offer a wide selection of HIV medications, often at competitive prices. They may also provide telemedicine services, enabling patients to consult with healthcare professionals remotely. The online pharmacy segment has seen significant growth, particularly in regions with robust e-commerce infrastructure, and it serves as an option for individuals who face barriers to traditional pharmacy access.

Breakup by Region:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

North America leads the market, accounting for the largest HIV drugs market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America dominates the global HIV drugs market due to its well-developed healthcare infrastructure, high awareness about HIV/AIDS, and access to advanced antiretroviral therapies. The region is characterized by extensive research and development activities, a large patient population, and significant government funding for HIV/AIDS programs. Furthermore, the presence of major pharmaceutical companies in North America contributes to the market's growth. The focus here is on innovative treatments, combination therapies, and efforts to reduce new infections through comprehensive prevention strategies.

Europe is a substantial market for HIV drugs, characterized by a well-regulated healthcare system and access to state-of-the-art treatments. The region has made progress in reducing HIV transmission rates, but it continues to face challenges related to stigma and late diagnosis. The market in Europe is driven by increasing awareness, comprehensive healthcare coverage, and collaborations between healthcare providers and pharmaceutical companies to improve patient outcomes. Additionally, research into long-acting therapies and preventive measures like PrEP contributes to the market's development.

The Asia Pacific region is witnessing rapid growth in the HIV drugs market due to its large and diverse population, including many individuals living with HIV. This segment faces unique challenges, such as varying healthcare infrastructure, economic disparities, and culturally diverse populations. Increased efforts to expand access to treatment, raise awareness, and reduce new infections are driving market growth. Generic medications and government initiatives to combat HIV/AIDS play a significant role in the Asia Pacific market. Moreover, collaborations with international organizations and NGOs are enhancing the region's response to the HIV epidemic.

Latin America has a growing HIV drugs market, driven by the expanding healthcare infrastructure and increased access to treatment and prevention programs. The region faces challenges related to inequality and limited access to healthcare services in some areas. However, initiatives to improve healthcare coverage, raise awareness, and expand access to antiretroviral therapies are driving market growth. Collaboration between governments, pharmaceutical companies, and non-profit organizations is critical to addressing the HIV/AIDS epidemic in Latin America.

The Middle East and Africa represent a diverse and challenging market for HIV drugs. While access to treatment has improved in some countries, significant disparities persist due to economic and healthcare infrastructure differences. The region faces cultural and social stigma related to HIV/AIDS, which can hinder diagnosis and treatment. Nonetheless, efforts to expand access to medications, increase awareness, and promote preventive measures are ongoing. Partnerships with international organizations and global health initiatives are crucial in addressing the unique challenges in the Middle East and Africa.

Leading Key Players in the HIV Drugs Industry:

Key players in the global HIV drugs market are actively engaged in several strategic initiatives. They are focusing on research and development to innovate and improve existing antiretroviral therapies, aiming for more convenient dosing regimens, fewer side effects, and enhanced treatment outcomes. These companies are also expanding their product portfolios by developing new drugs and combination therapies. Additionally, they are collaborating with governments, NGOs, and healthcare providers to increase access to HIV medications in resource-limited regions and to implement preventive measures. Furthermore, these pharmaceutical giants are investing in awareness campaigns and education to reduce HIV stigma and promote early diagnosis and treatment.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Boehringer Ingelheim International GmbH

Merck & Co., Inc.

ViiV Healthcare

AbbVie

F. Hoffmann-La Roche Ltd.

Teva Pharmaceutical Industries Ltd.

Bristol-Myers Squibb Gilead Sciences, Inc.

Johnson & Johnson

Cipla Limited

Daiichi Sankyo

Emcure Pharmaceuticals

Hetero Drugs

Mylan N.V

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Latest News:

2021: Merc received approval from the U.S. Food and Drug Administration (FDA) for its new antiretroviral drug, Isentress HD, which offers improved dosing convenience for patients. The introduction of ISENTRESS HD reflects Merck's commitment to innovation in HIV therapy, offering a broader range of treatment options to fit the individual needs and lifestyles of people living with HIV. The price of ISENTRESS HD is set to be the same as the twice-daily ISENTRESS, and it was anticipated to be available in pharmacies approximately four weeks following the approval announcement.

June 2022: Cipla Ltd. and its partner Drugs for Neglected Diseases Initiative (DNDi) reported the availability of a 4-in-1 antiretroviral medication for younger children. This innovative treatment has been approved by the South African Health Products Regulatory Authority (SAHPRA) and is specifically designed for infants and young children living with HIV.

In 2021: Johnson & Johnson has also been actively involved in the development of HIV drugs. In 2021, the company received FDA approval for its new antiretroviral drug, Rekambys, which is a long-acting injectable treatment option for HIV-1 infection in certain patients.

Key Questions Answered in This Report

• 1. What was the size of the global HIV drugs market in 2023?
• 2. What is the expected growth rate of the global HIV drugs market during 2024-2032?
• 3. What has been the impact of COVID-19 on the global HIV drugs market?
• 4. What are the key factors driving the global HIV drugs market?
• 5. What is the breakup of the global HIV drugs market based on the drug class?
• 6. What is the breakup of the global HIV drugs market based on the distribution channel?
• 7. What are the key regions in the global HIV drugs market?
• 8. Who are the key players/companies in the global HIV drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global HIV Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Price Analysis
• 5.5 Market Breakup by Drug Class
• 5.6 Market Breakup by Distribution Channel
• 5.7 Market Breakup by Region
• 5.8 Market Forecast
• 5.9 SWOT Analysis
  • 5.9.1 Overview
  • 5.9.2 Strengths
  • 5.9.3 Weaknesses
  • 5.9.4 Opportunities
  • 5.9.5 Threats
• 5.10 Value Chain Analysis
  • 5.10.1 Overview
  • 5.10.2 Research and Development
  • 5.10.3 Raw Material Procurement
  • 5.10.4 Manufacturing
  • 5.10.5 Marketing
  • 5.10.6 Distribution
  • 5.10.7 End-Use
• 5.11 Porters Five Forces Analysis
  • 5.11.1 Overview
  • 5.11.2 Bargaining Power of Buyers
  • 5.11.3 Bargaining Power of Suppliers
  • 5.11.4 Degree of Competition
  • 5.11.5 Threat of New Entrants
  • 5.11.6 Threat of Substitutes

6 Market Breakup by Drug Class

• 6.1 Nucleoside Reverse Transcriptase Inhibitors
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Multi-Class Combination Products
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Protease Inhibitors
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 HIV Integrase Strand Transfer Inhibitors
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Non-Nucleoside Reverse Transcriptase Inhibitors
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Entry Inhibitors - CCR5 Co-Receptor Antagonist
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast
• 6.7 Fusion Inhibitors and Others
  • 6.7.1 Market Trends
  • 6.7.2 Market Forecast

7 Market Breakup by Distribution Channel

• 7.1 Hospital Pharmacies
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Retail Pharmacies
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Online Pharmacies
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Europe
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Asia Pacific
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Middle East and Africa
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Latin America
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 HIV Drugs Manufacturing Process

• 9.1 Product Overview
• 9.2 Raw Material Requirements
• 9.3 Manufacturing Process
• 9.4 Key Success and Risk Factors

10 Competitive Landscape

• 10.1 Market Structure
• 10.2 Market Breakup by Key Players
• 10.3 Profiles of Key Players
  • 10.3.1 Boehringer Ingelheim International GmbH
  • 10.3.2 Merck & Co., Inc.
  • 10.3.3 ViiV Healthcare
  • 10.3.4 AbbVie
  • 10.3.5 F. Hoffmann-La Roche Ltd.
  • 10.3.6 Teva Pharmaceutical Industries Ltd.
  • 10.3.7 Bristol-Myers Squibb
  • 10.3.8 Gilead Sciences, Inc.
  • 10.3.9 Johnson & Johnson
  • 10.3.10 Cipla Limited
  • 10.3.11 Daiichi Sankyo
  • 10.3.12 Emcure
  • 10.3.13 Hetero Drugs
  • 10.3.14 Mylan

List of Figures

• Figure 1: Global: HIV Drugs Market: Major Drivers and Challenges
• Figure 2: Global: HIV Drugs Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: HIV Drugs Market: Breakup by Drug Class (in %), 2023
• Figure 4: Global: HIV Drugs Market: Breakup by Distribution Channel (in %), 2023
• Figure 5: Global: HIV Drugs Market: Breakup by Region (in %), 2023
• Figure 6: Global: HIV Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 7: Global: HIV Drugs Industry: SWOT Analysis
• Figure 8: Global: HIV Drugs Industry: Value Chain Analysis
• Figure 9: Global: HIV Drugs Industry: Porter's Five Forces Analysis
• Figure 10: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 11: Global: HIV Drugs (Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 12: Global: HIV Drugs (Multi-Class Combination Products) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 13: Global: HIV Drugs (Multi-Class Combination Products) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 14: Global: HIV Drugs (Protease Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 15: Global: HIV Drugs (Protease Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 16: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 17: Global: HIV Drugs (HIV Integrase Strand Transfer Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 18: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 19: Global: HIV Drugs (Non-Nucleoside Reverse Transcriptase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 20: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 21: Global: HIV Drugs (Entry Inhibitors - CCR5 Co-Receptor Antagonist) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 22: Global: HIV Drugs (Fusion Inhibitors and Others) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 23: Global: HIV Drugs (Fusion Inhibitors and Others) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 24: Global: HIV Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2018 & 2023
• Figure 25: Global: HIV Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2024-2032
• Figure 26: Global: HIV Drugs Market: Sales through Retail Pharmacies (in Million US$), 2018 & 2023
• Figure 27: Global: HIV Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2024-2032
• Figure 28: Global: HIV Drugs Market: Sales through Online Pharmacies (in Million US$), 2018 & 2023
• Figure 29: Global: HIV Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2024-2032
• Figure 30: Global: HIV Drugs Market: Sales through Other Distribution Channels (in Million US$), 2018 & 2023
• Figure 31: Global: HIV Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2024-2032
• Figure 32: North America: HIV Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 33: North America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 34: Europe: HIV Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 35: Europe: HIV Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 36: Asia Pacific: HIV Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 37: Asia Pacific: HIV Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 38: Middle East and Africa: HIV Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 39: Middle East and Africa: HIV Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 40: Latin America: HIV Drugs Market: Sales Value (in Million US$), 2018 & 2023
• Figure 41: Latin America: HIV Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 42: HIV Drugs Manufacturing: Detailed Process Flow
• Figure 43: Global: HIV Drugs Market: Breakup by Key Players (in %)

List of Tables

• Table 1: Global: HIV Drugs Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: HIV Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
• Table 3: Global: HIV Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
• Table 4: Global: HIV Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 5: HIV Drugs Manufacturing: Raw Material Requirements
• Table 6: Global: HIV Drugs Market: Competitive Structure
• Table 7: Global: HIV Drugs Market: Key Players